NCT06011590

QRS Microfragmentation in ECG as Predictor of Mortality and Morbidity - a Retrospective Analysis

Completed Last updated 25 August 2023

What this trial tests

trial testing No intervention. in Risk Stratification in 150,000 participants. Completed in 31 July 2022.

Timeline

1 January 2000

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	Medical University Innsbruck
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150,000
Start date	1 January 2000
Primary completion	31 July 2022
Estimated completion	31 July 2022

Drugs / interventions tested

• No intervention.

Conditions studied

• Risk Stratification — all drugs for Risk Stratification →

Sponsor

Medical University Innsbruck

Who can join

18 and older, any sex, with Risk Stratification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Over the past decades, several ECG-based parameters have been identified as independent predictors of worsened prognosis in affected patients. In addition to visual assessment of morphology, methods of computer-based machine ECG analysis have gained importance in recent years. These methods allow the detection of systemic abnormalities in ECGs that are not visible to the naked eye. An example of this is provided by the so-called "QRS microfragmentations".

The aim of this evaluation is to retrospectively collect all established as well as new quantitative and qualitative ECG parameters (such as QRS microfragmentation) in a large patient collective. Subsequently, after characterization of the patients, an independent multivariate risk prediction model should be developed based on computer-based ECG analysis using maschnine learning algorithms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.